Peer-reviewed veterinary case report
Perna canaliculus oil helps dogs with pulmonary hypertension cough
By Riengvirodkij, Nattapon et al.·Published in PloS one·2025·Prasu Arthorn Veterinary Teaching Hospital·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough.
- Species:
- dog
Plain-English summary
A group of dogs with pulmonary hypertension (PH), which causes high blood pressure in the lungs, were given either a marine oil supplement called Perna canaliculus oil (PCSO-524) or a placebo along with their regular medication, sildenafil. Over 70 days, the dogs receiving PCSO-524 showed significant improvements in their ability to exercise and had less coughing compared to those on the placebo. While all dogs experienced a decrease in pulmonary pressure, the PCSO-524 group had better overall clinical signs. This suggests that adding PCSO-524 could help improve the quality of life for dogs suffering from PH.
People also search for: dog pulmonary hypertension treatment · PCSO-524 for dogs · sildenafil for dog cough · improving dog exercise tolerance · dog cough remedies
Abstract
Pulmonary hypertension (PH) in dogs, characterized by abnormally high blood pressure in the pulmonary arteries, presents a management challenge, and adjunctive therapies for the standard treatment of sildenafil are needed. This study aimed to determine whether the nutraceutical Perna canaliculus oil (PCSO-524), a marine lipid extract with anti-inflammatory properties, provides additional clinical benefits to dogs with PH. In a prospective, randomized, placebo-controlled trial, seventeen client-owned dogs diagnosed with PH were assigned to receive either PCSO-524 or a placebo as an add-on to their sildenafil-based therapy for 70 days. Key outcomes were evaluated using owner-assessed clinical scores for exercise tolerance and coughing, alongside echocardiographic measurements. The PCSO-524 group demonstrated a statistically significant improvement in exercise tolerance scores by day 70 (P = 0.009). This group also showed a greater reduction in coughing scores compared to the placebo group between day 35 and day 70 (P = 0.03). While the tricuspid regurgitation pressure gradient (TRPG), an estimate of pulmonary pressure, decreased significantly over time in all dogs (P = 0.001), no significant difference was found between the groups for this specific measure. These results indicate that PCSO-524 can serve as a beneficial adjunctive therapy for improving important clinical signs, such as exercise tolerance and coughing, in dogs with PH. This suggests it may be a valuable addition to standard management for enhancing quality of life.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41021602/